- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 505240, 8 pages
A New Parasiticidal Compound in T. solium Cysticercosis
1Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, AP 70228, 04510 México, DF, Mexico
2Departamento de Microbiología, Facultad de Medicina, Universidad Autónoma de Nuevo León, 64460 Monterrey, NL, Mexico
3Unidad de Medicina Experimental, Hospital General de México, 06726 México, DF, Mexico
4Hollis-Eden Pharmaceuticals, Inc., San diego, CA 92121, USA
Received 31 July 2012; Revised 29 September 2012; Accepted 13 October 2012
Academic Editor: Abhay R. Satoskar
Copyright © 2013 Romel Hernández-Bello et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- T. E. Nash, G. Singh, A. C. White et al., “Treatment of neurocysticercosis: current status and future research needs,” Neurology, vol. 67, no. 7, pp. 1120–1127, 2006.
- H. H. Garcia and O. H. Del Brutto, “Neurocysticercosis: updated concepts about an old disease,” Lancet Neurology, vol. 4, no. 10, pp. 653–661, 2005.
- A. Flisser, E. Sarti, M. Lightowlers, and P. Schantz, “Neurocysticercosis: regional status, epidemiology, impact and control measures in the Americas,” Acta Tropica, vol. 87, no. 1, pp. 43–51, 2003.
- A. C. White Jr., “Neurocysticercosis: a major cause of neurological disease worldwide,” Clinical Infectious Diseases, vol. 24, no. 2, pp. 101–115, 1997.
- P. C. Fan and W. C. Chung, “Sociocultural factors and local customs related to taeniasis in east Asia,” The Kaohsiung Journal of Medical Sciences, vol. 13, no. 11, pp. 647–652, 1997.
- A. E. Gonzalez, C. Gavidia, N. Falcon et al., “Protection of pigs with cysticercosis from further infections after treatment with oxfendazole,” American Journal of Tropical Medicine and Hygiene, vol. 65, no. 1, pp. 15–18, 2001.
- Z. Pawlowski, J. Allan, and E. Sarti, “Control of Taenia solium taeniasis/cysticercosis: from research towards implementation,” International Journal for Parasitology, vol. 35, no. 11-12, pp. 1221–1232, 2005.
- C. B. Behravesh, L. F. Mayberry, J. R. Bristol et al., “Population-based survey of taeniasis along the United States-Mexico border,” Annals of Tropical Medicine and Parasitology, vol. 102, no. 4, pp. 325–333, 2008.
- A. C. Moore, L. I. Lutwick, P. M. Schantz et al., “Seroprevalence of cysticercosis in an orthodox Jewish community,” American Journal of Tropical Medicine and Hygiene, vol. 53, no. 5, pp. 439–442, 1995.
- P. M. Schantz, A. C. Moore, J. L. Munoz et al., “Neurocysticercosis in an Orthodox Jewish community in New York City,” New England Journal of Medicine, vol. 327, no. 10, pp. 692–695, 1992.
- M. T. Rabiela, Y. Hornelas, C. García-Allan, E. Rodríguez-del-Rosal, and A. Flisser, “Evagination of Taenia solium cysticerci: a histologic and electron microscopy study,” Archives of Medical Research, vol. 31, no. 6, pp. 605–607, 2000.
- B. Allolio and W. Arit, “DHEA treatment: myth or reality?” Trends in Endocrinology and Metabolism, vol. 13, no. 7, pp. 288–294, 2002.
- R. M. Loria and D. A. Padgett, “Control of the immune response by DHEA and its metabolites,” Rinsho Byori, vol. 46, no. 6, pp. 505–517, 1998.
- K. R. Rasmussen and M. C. Healey, “Dehydroepiandrosterone-induced reduction of Cryptosporidium parvum infections in aged Syrian golden hamsters,” Journal of Parasitology, vol. 78, no. 3, pp. 554–557, 1992.
- J. D. Kurtis, R. Mtalib, F. K. Onyango, and P. E. Duffy, “Human resistance to Plasmodium falciparum increases during puberty and is predicted by dehydroepiandrosterone sulfate levels,” Infection and Immunity, vol. 69, no. 1, pp. 123–128, 2001.
- J. C. Carrero, C. Cervantes, N. Moreno-Mendoza, E. Saavedra, J. Morales-Montor, and J. P. Laclette, “Dehydroepiandrosterone decreases while cortisol increases in vitro growth and viability of Entamoeba histolytica,” Microbes and Infection, vol. 8, no. 2, pp. 323–331, 2006.
- P. G. Fallon, E. J. Richardson, F. M. Jones, and D. W. Dunne, “Dehydroepiandrosterone sulfate treatment of mice modulates infection with Schistosoma mansoni,” Clinical and Diagnostic Laboratory Immunology, vol. 5, no. 2, pp. 251–253, 1998.
- J. A. Vargas-Villavicencio, C. Larralde, and J. Morales-Montor, “Treatment with dehydroepiandrosterone in vivo and in vitro inhibits reproduction, growth and viability of Taenia crassiceps metacestodes,” International Journal for Parasitology, vol. 38, no. 7, pp. 775–781, 2008.
- R. Hernández-Pando, D. Aguilar-Leon, H. Orozco et al., “16α-Bromoepiandrosterone restores T helper cell type 1 activity and accelerates chemotherapy-induced bacterial clearance in a model of progressive pulmonary tuberculosis,” Journal of Infectious Diseases, vol. 191, no. 2, pp. 299–306, 2005.
- N. C. Pedersen, T. W. North, R. Rigg et al., “16α-Bromo-epiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: initial enhancement leading to long-term suppression,” Veterinary Immunology and Immunopathology, vol. 94, no. 3-4, pp. 133–148, 2003.
- D. Freilich, S. Ferris, M. Wallace et al., “16α-bromoepiandrosterone, a dehydroepiandrosterone (DHEA) analogue, inhibits Plasmodium falciparum and Plasmodium berghei growth,” American Journal of Tropical Medicine and Hygiene, vol. 63, no. 5-6, pp. 280–283, 2000.
- G. Escobedo, C. W. Roberts, J. C. Carrero, and J. Morales-Montor, “Parasite regulation by host hormones: an old mechanism of host exploitation?” Trends in Parasitology, vol. 21, no. 12, pp. 588–593, 2005.
- R. T. Damian, “Parasite immune evasion and exploitation: reflections and projections,” Parasitology, vol. 115, supplement, pp. 169–175, 1997.
- M. Shibayama, J. D. J. Serrano-Luna, S. Rojas-Hernández, R. Campos-Rodríguez, and V. Tsutsumi, “Interaction of secretory immunoglobulin A antibodies with Naegleria fowleri trophozoites and collagen type I,” Canadian Journal of Microbiology, vol. 49, no. 3, pp. 164–170, 2003.
- F. Remoué, J. C. Mani, M. Pugnière, A. M. Schacht, A. Capron, and G. Riveau, “Functional specific binding of testosterone to Schistosoma haematobium 28-kilodalton glutathione S-transferase,” Infection and Immunity, vol. 70, no. 2, pp. 601–605, 2002.
- C. Konrad, A. Kroner, M. Spiliotis, R. Zavala-Góngora, and K. Brehm, “Identification and molecular characterisation of a gene encoding a member of the insulin receptor family in Echinococcus multilocularis,” International Journal for Parasitology, vol. 33, no. 3, pp. 301–312, 2003.
- M. Spiliotis, C. Konrad, V. Gelmedin et al., “Characterisation of EmMPK1, an ERK-like MAP kinase from Echinococcus multilocularis which is activated in response to human epidermal growth factor,” International Journal for Parasitology, vol. 36, no. 10-11, pp. 1097–1112, 2006.
- K. Brehm and M. Spiliotis, “The influence of host hormones and cytokines on echinococcus multilocuiaris signalling and development,” Parasite, vol. 15, no. 3, pp. 286–290, 2008.
- G. W. Esch and J. D. Smyth, “Studies on the in vitro culture of Taenia crassiceps,” International Journal for Parasitology, vol. 6, no. 2, pp. 143–149, 1976.
- S. León-Cabrera, M. Cruz-Rivera, F. Mendlovic et al., “Standardization of an experimental model of human taeniosis for oral vaccination,” Methods, vol. 49, no. 4, pp. 346–350, 2009.
- J. Morales-Montor, E. Newhouse, F. Mohamed, A. Baghdadi, and R. T. Damian, “Altered levels of hypothalamic-pituitary-adrenocortical axis hormones in baboons and mice during the course of infection with Schistosoma mansoni,” Journal of Infectious Diseases, vol. 183, no. 2, pp. 313–320, 2001.
- A. J. C. Fulford, M. Webster, J. H. Ouma, G. Kimani, D. W. Dunne, and T. Fulford, “Puberty and age-related changes in susceptibility to schistosome infection,” Parasitology Today, vol. 14, no. 1, pp. 23–26, 1998.
- C. D. Dos Santos, M. P. Alonso Toldo, and J. C. Do Prado, “Trypanosoma cruzi: the effects of dehydroepiandrosterone (DHEA) treatment during experimental infection,” Acta Tropica, vol. 95, no. 2, pp. 109–115, 2005.
- K. R. Rasmussen, E. G. Martin, and M. C. Healey, “Effects of dehydroepiandrosterone in immunosuppressed rats infected with Cryptosporidium parvum,” Journal of Parasitology, vol. 79, no. 3, pp. 364–370, 1993.
- K. R. Rasmussen, M. C. Healey, L. Cheng, and S. Yang, “Effects of dehydroepiandrosterone in immunosuppressed adult mice infected with Cryptosporidium parvum,” Journal of Parasitology, vol. 81, no. 3, pp. 429–433, 1995.
- K. Ayi, G. Giribaldi, A. Skorokhod, E. Schwarzer, P. T. Prendergast, and P. Arese, “16α-bromoepiandrosterone, an antimalarial analogue of the hormone dehydroepiandrosterone, enhances phagocytosis of ring stage parasitized erythrocytes: a novel mechanism for antimalarial activity,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 10, pp. 3180–3184, 2002.
- I. Safeukui, F. Mangou, D. Malvy et al., “Plasmodium berghei: dehydroepiandrosterone sulfate reverses chloroquino-resistance in experimental malaria infection; correlation with glucose 6-phosphate dehydrogenase and glutathione synthesis pathway,” Biochemical Pharmacology, vol. 68, no. 10, pp. 1903–1910, 2004.
- N. Maninger, O. M. Wolkowitz, V. I. Reus, E. S. Epel, and S. H. Mellon, “Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS),” Frontiers in Neuroendocrinology, vol. 30, no. 1, pp. 65–91, 2009.
- S. Couillard, C. Labrie, A. Bélanger, B. Candas, F. Pouliot, and F. Labrie, “Effect of dehydroepiandrosterone and antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts,” Journal of the National Cancer Institute, vol. 90, no. 10, pp. 772–778, 1998.
- E. Brignardello, C. Runzo, M. Aragno et al., “Dehydroepiandrosterone administration counteracts oxidative imbalance and advanced glycation end product formation in type 2 diabetic patients,” Diabetes Care, vol. 30, no. 11, pp. 2922–2927, 2007.
- D. R. Stickney, Z. Noveljic, A. Garsd, D. A. Destiche, and J. M. Frincke, “Safety and activity of the immune modulator HE2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patients,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 7, pp. 2639–2641, 2007.
- C. Reading, C. Dowding, B. Schramm et al., “Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16α-bromoepiandrosterone (HE2000),” Clinical Microbiology and Infection, vol. 12, no. 11, pp. 1082–1088, 2006.
- J. M. Frincke, D. R. Stickney, N. Onizuka-Handa et al., “Reduction of parasite levels in patients with uncomplicated malaria by treatment with HE2000,” American Journal of Tropical Medicine and Hygiene, vol. 76, no. 2, pp. 232–236, 2007.